Nasdaq · CIK 0001689548 · PHARMACEUTICAL PREPARATIONS
PRAXIS PRECISION MEDICINES, INC.
PRAX chart by TradingView
PRICE HISTORY
LIVE · NASDAQPRAX chart by TradingView
- REVENUE FY2025 ENDED DEC 2025
- $0.0B
- EBITDA
- $-0.3B
- FREE CASH FLOW
- $-0.2B
- EPS
- $-13.48
- GROSS MARGIN
- —
- ROIC
- —
Q4 FY25ENDED DEC 2025HOVERDRAG ACROSS ANY CHART TO SCRUB ALL 24 · 16 QUARTERS SHOWNVALUATIONGROWTHPROFITABILITY & RETURNSCASH & CAPITALBALANCE SHEET
VALUATION
what you pay for a unit of the business7 CHARTS⤢
P / E RATIO (TTM)
—
⤢
P / SALES (TTM)
—
+148%54.8x677.0x
⤢
P / BOOK
7.4x
+204%0.7x7.4x
⤢
EV / EBITDA (TTM)
—
⤢
EV / REVENUE (TTM)
—
⤢
FCF YIELD (TTM)
-3.85%
+166.4pp-381.60%-3.85%
⤢
DIVIDEND YIELD (TTM)
—
GROWTH
is the business getting bigger5 CHARTS⤢
REVENUE
$0.0B
+$0.0B⤢
EBITDA (DERIVED)
$-0.1B
$0.0B⤢
NET INCOME
$-0.1B
$0.0B⤢
EPS (DILUTED)
$-4.05
+$18.63⤢
REVENUE GROWTH YOY
-100.00%
-63.1pp-100.00%1349.13%
PROFITABILITY & RETURNS
what survives to the bottom, and what it earns on capital4 CHARTS⤢
FCF MARGIN
—
-4296.9pp-9105.96%-3996.67%
⤢
RETURN ON CAPITAL
—
⤢
RETURN ON EQUITY (TTM)
-34.54%
+246.7pp-283.50%-29.53%
MARGIN FUNNEL
every line is a share of the same revenue, so they read on one scale — the gaps are what each layer takes out, and net rises above operating when income arrives from outside the businessGROSS MARGIN—
OPERATING MARGIN—
NET MARGIN—
FCF MARGIN—
CASH & CAPITAL
where the money actually goes5 CHARTS⤢
FREE CASH FLOW
$-0.1B
$0.0B⤢
STOCK-BASED COMP
$0.0B
+26%⤢
CAPITAL EXPENDITURE
$0.0B
-100%⤢
SHARES OUTSTANDING
0.02B
+625%⤢
DIVIDEND / SHARE
—
BALANCE SHEET
how much cushion there is3 CHARTS⤢
CASH & EQUIVALENTS
$0.4B
+359%⤢
TOTAL DEBT
—
⤢
DEBT / EBITDA (TTM)
—
OWNERSHIP
10 LARGEST HOLDERS · WHO OWNS THE FLOATINSTITUTIONS 118.68%INSIDERS 0.28%OTHER / RETAIL 0.00%408 INSTITUTIONAL FILERS
| HOLDER | % HELD | SHARES | VALUE | CHANGE |
|---|---|---|---|---|
| Janus Henderson Group PLC | 12.41% | 3.5M | $1.25B | +6.8% |
| Orbis Allan Gray Ltd | 8.87% | 2.5M | $892.0M | +97.0% |
| Blackrock Inc. | 8.34% | 2.3M | $838.7M | +11.9% |
| FMR, LLC | 7.75% | 2.2M | $779.6M | +59.1% |
| Perceptive Advisors Llc | 7.30% | 2.0M | $734.5M | +2.0% |
| Baker Bros. Advisors, LP | 6.29% | 1.8M | $632.5M | +55.6% |
| Vanguard Capital Management LLC | 4.38% | 1.2M | $440.8M | NEW |
| Deerfield Management Company, L.P | 3.46% | 963K | $347.5M | +6.6% |
| Driehaus Capital Management, LLC | 3.40% | 949K | $342.4M | +1.7% |
| Cormorant Asset Management, LP | 3.18% | 886K | $319.5M | -6.8% |
AS OF 2026-03-31 · MOST RECENT 13F FILINGS
SOURCE → 10-K · 10-Q · 8-K / GUIDANCE · ALL FILINGS
FILING DATA AS OF 2026-08-10. Figures are derived from public SEC EDGAR filings (40most recent quarters shown, Q4 implied as full-year minus Q1-Q3). Valuation multiples use each period’s fiscal period-end close. Live price charts and quotes are provided by TradingView. This page is informational only — it is not investment advice, and figures are not warranted for accuracy. EBITDA is not a GAAP measure; it is derived as operating income + D&A. Verify against the linked source filing before relying on any number here.
FILING DATA AS OF 2026-08-10. Figures are derived from public SEC EDGAR filings (40most recent quarters shown, Q4 implied as full-year minus Q1-Q3). Valuation multiples use each period’s fiscal period-end close. Live price charts and quotes are provided by TradingView. This page is informational only — it is not investment advice, and figures are not warranted for accuracy. EBITDA is not a GAAP measure; it is derived as operating income + D&A. Verify against the linked source filing before relying on any number here.